There have been no reported cases of overdosage with Visicol® Tablets. Purposeful or accidental ingestion of more than the recommended dosage of Visicol® Tablets might be expected to lead to severe electrolyte disturbances, including hyperphosphatemia, hypocalcemia, hypernatremia, or hypokalemia, as well as dehydration and hypovolemia, with attendant signs and symptoms of these disturbances. Certain severe electrolyte disturbances may lead to cardiac arrhythmias and death. The patient who has taken an overdosage should be monitored carefully, and treated symptomatically for complications until stable.

Visicol^® Tablets are not to be used in patients with congestive heart failure, ascites, unstable angina pectoris, gastric retention, ileus or acute obstruction or pseudo-obstruction, severe chronic constipation, bowel perforation, acute colitis, toxic megacolon, or hypomotility syndrome (associated with, e.g., scleroderma, inadequately treated hypothyroidism).

Visicol® Tablets are contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients.

Bookmark this page: